Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Undergoing PCI
2006-000192-14Phase 3Terminated
- Sponsor
- The Medicines Company
- Start
- Nov 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cangrelor in coronary arteriosclerosis and myocardial infarction (MI) (2 arms), sponsored by The Medicines Company. Primary endpoint: Primary efficacy composite endpoint at 48 hours. Started Nov 2006; status: terminated.
02
Drugs
cangrelor
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on 2006-000192-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000192-14.